CN113227080A - 2, 4-diaminopyrimidine derivatives - Google Patents

2, 4-diaminopyrimidine derivatives Download PDF

Info

Publication number
CN113227080A
CN113227080A CN201980086260.6A CN201980086260A CN113227080A CN 113227080 A CN113227080 A CN 113227080A CN 201980086260 A CN201980086260 A CN 201980086260A CN 113227080 A CN113227080 A CN 113227080A
Authority
CN
China
Prior art keywords
alkyl
halogen
heteroalkyl
cancer
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980086260.6A
Other languages
Chinese (zh)
Other versions
CN113227080B (en
Inventor
张磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Zheye Biotechnology LLC
Original Assignee
Shanghai Zheye Biotechnology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Zheye Biotechnology LLC filed Critical Shanghai Zheye Biotechnology LLC
Publication of CN113227080A publication Critical patent/CN113227080A/en
Application granted granted Critical
Publication of CN113227080B publication Critical patent/CN113227080B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Abstract

The invention relates to a 2, 4-diaminopyrimidine derivative, pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof, a preparation method thereof and application of the compound in treating diseases with ALK2 kinase-mediated pathological characteristics by being used alone or in combination with other medicines

Description

2, 4-diaminopyrimidine derivatives Technical Field
The invention relates to a2, 4-diaminopyrimidine derivative, a pharmaceutically acceptable salt, a hydrate, a solvate or a stereoisomer thereof, a preparation method thereof and application of the compound in treating diseases with ALK2 kinase-mediated pathological characteristics by using the compound alone or in combination with other medicines.
Background
Systemic iron balance is maintained by the coordinated regulation of duodenal iron absorption, iron recycling by aged red blood cells in macrophages, and mobilization of stored iron in the liver (Ganz T., Physiol Rev.2013; 93(4): 1721-1741). A key coordinator in this process is a small peptide hormone synthesized primarily in hepatocytes, Hepcidin (Krause A. et al, FEBS Lett.2000; 480 (2-3): 147-) 150; Pigeon C. et al, J Biol chem.2001; 276(11): 7811-. Hepcidin reduces the uptake of duodenal iron and iron export from monocytes/macrophages by binding to and inducing internalization and degradation of ferroportin (FPN1) (Hentze MW. et al, cell. 2010; 142(1): 24-38; Nemeth E. et al, science.2004; 306(5704): 2090-. Thus, elevated serum hepcidin levels enhance iron storage in the reticuloendothelial system and result in a decrease in available iron and the production of iron deficient erythrocytes. Abnormally elevated Hepcidin expression causes severe functional iron deficiency anemia in humans and is central to the pathophysiology of Anemia of Chronic Disease (ACD) (Weiss G. et al, N Engl J Med.2005; 352(10): 1011-. The transcription of Hepcidin in the liver is mainly influenced by several factors, including storage of body iron, iron requirement for red blood cell production, hypoxia and inflammatory response. Bone Morphogenic Proteins (BMPs) play an important role in mediating these factors and driving hepcidin transcription induction by activating BMP receptor (BMPR) -SMAD signaling (Wang RH. et al, Cell Metab.2005; 2(6): 399-. BMPR activin receptor-like kinase 2(ALK2) and ALK3 have shown an important role in this process, with liver-specific deletions of ALK2 or ALK3 blocking the induction of hepcidin production downstream of BMP ligand binding and leading to iron overload in mice (Steinbicker AU. et al, blood.2011; 118(15): 4224-.
BMP ligands interact with Bone Morphogenetic Protein Receptors (BMPRs), BNPRs belong to the serine/threonine kinase receptors of the TGF- β superfamily. Anemia arising from chronic infection, inflammation and malignancy is commonly referred to as chronicity anemia, and in these patients, BMP signaling induces hepatic expression of hepcidin through two BMP type I receptors, ALK2 and ALK 3. Hepcidin, by degrading iron output, iron transporters reduce blood iron levels, leading to increased iron storage in macrophages and other cells, and making it unavailable for hemoglobin and red blood cell function. Increasing iron intake does not reverse chronic Anemia (ACD) because iron intake due to BMP pathway activation and high plasma hepcidin levels is only stored. Blocking BMP signaling is a potential therapy for the treatment of anemia of chronic disease.
BMP signaling pathways also play an important role in the growth and progression of tumor cells, particularly breast, prostate, and other tumors that are prone to bone metastasis (Lin Ye. et al, Front biosci.2011(16): 865-897). BMPs and BMPRs are more highly expressed in metastatic breast cancer than in non-metastatic, and also highly expressed in bone-metastatic prostate cancer. These results indicate that BMP inhibitors may be able to prevent bone metastasis.
Disclosure of Invention
The invention aims to provide a compound shown in a formula (I) or pharmaceutically acceptable salt, hydrate, solvate or stereoisomer thereof,
Figure PCTCN2019128246-APPB-000001
wherein:
x is- (CR)7R 8) p-；
R 1Selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, 3-to 8-membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl, wherein alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted;
R 2selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9or-NR9COR 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 3、R 4and R5Each independently selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl, wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl, saturated or unsaturated heterocyclyl, oxo or 3-8 membered cycloalkyl; wherein the alkyl, alkenyl, alkynyl, heterocyclic or cycloalkyl group may be optionally substituted;
R 9、R 10and R11Each independently selected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R12Substituted saturated or unsaturated heterocyclic ring;
each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
m is 0, 1,2 or 3;
p is 1,2 or 3;
q is 0, 1,2 or 3.
In another aspect, the invention provides a compound of formula (II),
Figure PCTCN2019128246-APPB-000002
wherein the content of the first and second substances,
x is- (CR)7R 8) p-；
R 1Selected from aryl or heteroaryl groups which may be optionally substituted;
R 2selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9or-NR9COR 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 3、R 4and R5Each independently selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl, wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl, saturated or unsaturated heterocyclyl, oxo or 3-8 membered cycloalkyl; wherein the alkyl, alkenyl, alkynyl, heterocyclic or cycloalkyl group may be optionally substituted;
R 9、R 10and R11Each independently selected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R12Substituted saturated or unsaturated heterocyclic ring;
each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
p is 1,2 or 3;
q is 0, 1,2 or 3.
In another aspect, the invention provides a compound of formula (III),
Figure PCTCN2019128246-APPB-000003
wherein the content of the first and second substances,
x is- (CR)7R 8) p-；
R 1Is selected from heteroaryl which may be optionally substituted;
R 2selected from-H, halogen or-C1-6An alkyl group; wherein alkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
R 3and R4Each independently selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、C 1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6An alkyl or heteroalkyl group, wherein the alkyl or heteroalkyl group may be optionally substituted;
R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl or oxo; wherein alkyl, alkenyl or alkynyl may be selected from-H, halogen, -C1-4Alkyl substituent substitution;
R 9、R 10and R11Are respectively and independentlySelected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R12Substituted saturated or unsaturated heterocyclic ring;
each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
p is 1,2 or 3;
q is 0, 1,2 or 3.
In a further embodiment, the present invention provides a compound of formula (III), a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
x is- (CR)7R 8) p-；
R 1Selected from pyridyl optionally substituted;
R 2selected from-H, halogen or-C1-6An alkyl group; wherein alkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
R 3and R4Each independently selected from-H, halogen, -C1-6Alkyl or heteroalkyl; wherein alkyl or heteroalkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
R 6selected from-H, halogen, -OH, -CN, -C1-6Alkyl or-C1-6An alkoxy group; wherein alkyl or alkoxy may be selected from-H, halogen, -C1-4Alkyl or oxo;
R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl or-C1-6Alkoxy, wherein alkyl or alkoxy may be selected from-H, halogen or-C1-4Alkyl substituent substitution;
p is 1 or 2.
In a further embodiment, the present invention provides a compound of formula (III), a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
x is- (CR)7R 8) p-；
R 1Is composed of
Figure PCTCN2019128246-APPB-000004
Wherein R is13Selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-NO 2、-NH 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl;
R 2selected from-H, halogen or C1-6An alkyl group;
R 3and R4Each independently selected from-H, halogen, C1-6Alkyl or-C1-6Alkoxy, wherein alkyl or alkoxy may be selected from-H, halogen or-C1-4Alkyl or oxo;
R 6selected from-H, halogen, -OH, -CN, -C1-6Alkyl or-C1-6An alkoxy group;
R 7and R8Each independently selected from-H, halogen or-C1-6Alkyl, wherein alkyl may be selected from-H, halogen or-C1-4Alkyl substituent substitution;
p is 1 or 2.
In a further embodiment, the present invention provides a compound of formula (III), a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
x is- (CR)7R 8) p-；
R 1Is composed of
Figure PCTCN2019128246-APPB-000005
Wherein R is13Selected from-H, halogen or-C1-4An alkyl group;
R 2is selected from-H or-C1-4An alkyl group;
R 3is selected from-H, -C1-4Alkyl or-C1-4An alkoxy group;
R 4is selected from-H or-C1-4An alkyl group;
R 6selected from-H, halogen, -CN, -C1-4Alkyl or-C1-4An alkoxy group;
R 7and R8Each independently selected from-H or-C1-4An alkyl group;
p is 1 or 2.
The present invention relates to typical compounds of formula (I) -formula (III) as follows, but is not limited to:
Figure PCTCN2019128246-APPB-000006
Figure PCTCN2019128246-APPB-000007
definition of
As used above and elsewhere herein, the following terms and abbreviations have the meanings defined below. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art.
Abbreviations Means of
ALK2 Activin receptor-like kinase 2
Hepcidin Hepcidin
FPN1 Membrane iron transport protein
ACD Anemia of chronic disease
BMPs Bone morphogenetic protein
BMPR Bone morphogenetic protein receptor
TGF-β Transforming growth factor-beta
TLC Thin layer chromatography
R f Ratio shift value
n-BuOH N-butanol
DCM Methylene dichloride
TFA Trifluoroacetic acid
EA Ethyl acetate
ADP Adenosine diphosphate
ATP Adenosine triphosphate
Ser/Thr Serine/threonine
The term "halogen" refers herein to-F, -Cl, -Br, and-I.
The term "alkyl" refers herein to an alkyl group that does not contain heteroatoms. Thus, the term includes straight chain alkyl groups such as methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like. The term also includes branched isomers of branched alkyl groups, including but not limited to, for example, the following groups: -CH (CH)3) 2、-CH(CH 3)(CH 2CH 3)、-CH(CH 2CH 3) 2、-C(CH 3) 3、 -C(CH 2CH 3) 3、-CH 2CH(CH 3) 2、-CH 2CH(CH 3)(CH 2CH 3)、-CH 2CH(CH 2CH 3) 2、-CH 2C(CH 3) 3、-CH 2C(CH 2CH 3) 3、-CH(CH 3)-CH(CH 3)(CH 2CH 3)、-CH 2CH 2CH(CH 3) 2、-CH 2CH 2CH(CH 3)(CH 2CH 3)、-CH 2CH 2CH(CH 2CH 3) 2、-CH 2CH 2C(CH 3) 3、-CH 2CH 2C(CH 2CH 3) 3、-CH(CH 3)CH 2CH(CH 3) 2、-CH(CH 3)CH(CH 3)CH(CH 3) 2、-CH(CH 2CH 3)CH(CH 3)CH(CH 3)(CH 2CH 3) And the like. The term alkyl thus includes primary, secondary and tertiary alkyl groups.
The term "alkenyl" refers herein to an alkyl group as defined above wherein there is at least one point of unsaturation, i.e., wherein two adjacent carbon atoms are connected by a double bond, wherein the alkyl group is as defined herein
The term "alkynyl" is referred to herein as relating to an alkyl group wherein two adjacent carbon atoms are connected by a triple bond, wherein the alkyl group is as defined herein.
The term "heteroalkyl" refers herein to an alkyl group that includes at least one heteroatom.
The term "cycloalkyl" refers herein to a mono-or polycyclic carbocycloalkyl substituent. Including cyclic alkyl, alkenyl, and alkynyl groups. The cycloalkyl group can be monocyclic or polycyclic (e.g., containing fused, bridged, and/or spiro ring systems) in which the carbon atom is located either inside or outside of the ring system. The cycloalkyl group as a whole may have 3 to 14 ring atoms (e.g., 3 to 8 carbon atoms for monocyclic cycloalkyl groups and 7 to 14 carbon atoms for polycyclic cycloalkyl groups). Any suitable ring position of the cycloalkyl group can be covalently linked to the defined chemical structure. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cycloheptatrienyl, norbornyl, norpinanyl, norcarane-yl, adamantyl, and spiro [4.5] decyl, and homologs and isomers thereof, and the like.
The term "heterocyclic" or "heterocycle" or "heterocyclyl" refers to a ring selected from: 4-12 membered monocyclic, bicyclic and tricyclic saturated and partially unsaturated rings containing at least one carbon atom in addition to 1,2, 3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen. "heterocycle" also refers to a 5-7 membered heterocycle fused to a 5, 6 and/or 7 membered cycloalkyl, carbocyclic aromatic or heterocyclic aromatic ring and containing at least one heteroatom selected from N, O and S, provided that the point of attachment is on the heterocycle when the heterocycle is fused to a carbocyclic aromatic or heteroaromatic ring and the point of attachment may be on the cycloalkyl or heterocycle when the heterocycle is fused to a cycloalkyl.
"heterocycle" also refers to an aliphatic spirocycle containing at least one heteroatom selected from N, O and S, provided that the point of attachment is on the heterocycle. The ring may be saturated or contain at least one double bond (i.e., partially unsaturated). The heterocyclic ring may be substituted with oxo (oxo). The point of attachment may be a carbon or heteroatom in a heterocycle. Heterocycles are not heteroaryl as defined herein.
Examples of heterocycles include, but are not limited to (numbered from the preferred attachment position 1) 1-pyrrolidinyl, 2, 4-imidazolidinyl, 2, 3-pyrazolidinyl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 2, 5-piperidinyl, pyranyl, 2-morpholinyl, 3-morpholinyl, oxiranyl (oxiranyl), aziridinyl (aziridinyl), thietanyl (thiiranyl), azetidinyl, oxetanyl, thietanyl, 1, 2-dithianyl, 1, 3-dithianyl, dihydropyridinyl, tetrahydropyridinyl, thiomorpholinyl, thiaoxazolidinyl (thioxanyl), piperazinyl, homopiperazinyl, homopiperidinyl, azepanyl (azepanyl), oxepanyl (oxapinanyl), Thiepanyl (thiepanyl), 1, 4-oxathiepanyl, 1, 4-dioxepanyl, 1, 4-oxathiepanyl, 1, 4-oxazepanyl, 1, 4-dithiacycloheptyl, 1, 4-thiazepanyl, and 1, 4-diazepinyl 1, 4-dithianyl, 1, 4-azathiepanyl, oxazepinyl, diazepinyl, thiazepinyl, dihydrothienyl, dihydropyranyl, dihydrofuranyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydrothiopyranyl, 1-pyrrolinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, 1, 4-dioxanyl, 1, 3-dioxolanyl, 1, 4-dioxetyl, Pyrazolinyl, pyrazolidinyl, dithiinyl, dithiocyclopentyl, pyrazolylimidazolinyl, pyrimidinonyl, 1-dioxo-thiomorpholinyl, 3-azabicyclo [3.1.0] hexanyl, 3-azabicyclo [4.1.0] heptanyl, azabicyclo [2.2.2] hexanyl. Substituted heterocycles also include ring systems substituted with one or more oxo moieties, such as pyrimidinyl N-oxide, morpholinyl-N-oxide, 1-oxo-1-thiomorpholinyl, and 1, 1-dioxo-1-thiomorpholinyl.
The term "aryl" refers to an aromatic ring in which each atom forming the ring is a carbon atom. Aryl rings may be formed from five, six, seven, eight, nine, or more than nine carbon atoms. The aryl group may be optionally substituted. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, phenanthryl, anthracyl, fluorenyl, and indenyl.
The term "heteroaryl" or alternatively "heteroaromatic group" refers to an aromatic group which includes one or more ring heteroatoms selected from nitrogen, oxygen and sulfur. The "heteroaromatic" or "heteroaryl" moiety containing N refers to an aromatic group in which at least one of the backbone atoms of the ring is a nitrogen atom. Illustrative examples of heteroaryl groups include the following moieties:
Figure PCTCN2019128246-APPB-000008
and the like. Depending on the structure, heteroaryl groups can be mono-or di-radical (i.e., heteroarylene groups).
The term "oxo" refers herein to (═ O) or (-O)-)。
The term "alkoxy" refers to a (alkyl) O-group, wherein alkyl is defined herein.
At various positions in this specification, substituents for the compounds of the invention are disclosed in the form of groups or ranges. This specifically means that the invention includes each member of such groups and ranges or subcombinations of each individual member of the members. Such as the term "C1-6Alkyl "specifically means that methyl, ethyl, C are disclosed separately3Alkyl radical, C4Alkyl radical, C5Alkyl and C6An alkyl group.
The term "compounds of the present invention" (unless specifically indicated otherwise) refers herein to compounds of formulae (I) - (III) and all pure and mixed stereoisomers, geometric isomers, tautomers, solvates, hydrates, prodrugs and isotopically labeled compounds and any pharmaceutically acceptable salts thereof. Solvates of the compounds of the invention refer to compounds or salts thereof, such as hydrates, ethanolates, methanolates, and the like, in combination with stoichiometric and non-stoichiometric amounts of solvent. The compound may also exist in one or more crystalline states, i.e., as co-crystals, polymorphs, or it may exist as an amorphous solid. All such forms are intended to be covered by the claims.
The term "pharmaceutically acceptable" means that the substance or composition must be compatible chemically and/or toxicologically with the other ingredients comprising the formulation and/or the mammal being treated therewith.
The term "stereoisomer" refers herein to compounds of different chirality having one or more stereocenters, including the enantiomers and diastereomers.
The compounds of the present invention may be used in the form of salts, such as "pharmaceutically acceptable salts" derived from inorganic or organic acids. These include, but are not limited to, the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, hydrochloride, 2-naphthalenesulfonate, oxalate, pectinate, sulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and decanoate. In addition, the basic nitrogen-containing groups can be quaternized with the following agents to form quaternary ammonium salts: such as lower alkyl halides including methyl, ethyl, propyl and butyl chlorides, bromides and iodides; such as dialkyl sulfates, including dimethyl, diethyl, dibutyl, and diamyl sulfates; such as long chain halides including decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; such as aralkyl halides, such as benzyl and phenethyl bromides, and the like.
The invention also includes isotopically-labelled compounds of the invention, i.e. those structures which are identical to those disclosed above, but in which one or more atoms are replaced by an atom having the same number of protons, but a different number of neutrons. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine, chlorine, iodine, respectively2H、 3H、 13C、 14C、 15N、 18O、 17O、 35S、 18F、 36Cl and131i, and the like. The compounds of the present invention, stereoisomers, tautomers or pharmaceutically acceptable salts thereof, as well as the compounds of the above forms containing the above isotopes and/or other atomic isotopes, are within the scope of the present invention. Certain isotopically-labelled compounds of the invention, e.g. by3H or14Those labeled with C can be used in drug tissue distribution assays, and thus, these3H or14The C isotope is particularly preferred because of its ease of preparation and detection. In addition, by heavier isotopes such as2Certain compounds of the invention substituted with H have certain therapeutic advantages due to their greater metabolic stability, such as increased in vivo half-life and lower dosages, and, therefore,2h is also preferred in some cases. Isotopically labeled compounds of formulae (I) - (III) of the present invention and prodrugs thereof can generally be prepared by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent in carrying out the procedures disclosed in the schemes and/or in the examples and preparations below.
Another aspect of the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formulae (I) - (III), or a pharmaceutically acceptable carrier, diluent or excipient thereof.
The invention further relates to application of the compounds in the general formulas (I) to (III) or pharmaceutically acceptable salts thereof or a pharmaceutical composition containing the compounds in preparation of medicines for preventing and/or treating diseases with ALK2 kinase-mediated pathological characteristics. Diseases with ALK2 kinase-mediated pathological features are selected from anemia or cancer.
The present invention also relates to a method for the therapeutic prevention and/or therapeutic prevention of a disease having an ALK2 kinase-mediated pathological feature, which comprises administering to a patient a therapeutically effective amount of a compound of the general formulae (I) - (III) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the disease having an ALK2 kinase-mediated pathological feature is selected from anemia or cancer.
The present invention also relates to a method for the therapeutic prevention and/or therapeutic prevention of a disease having a pathological feature mediated by ALK2kinase, which comprises administering to a patient a therapeutically effective amount of a compound of the general formulae (I) - (III) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the disease having a pathological feature mediated by ALK2kinase is selected from anemia, wherein the anemia is selected from anemia of chronic disease, anemia of chronic inflammation, cancer, or anemia of progressive fibrodysplasia.
The present invention also relates to a method for the treatment and/or prophylaxis of a disease having a pathological feature mediated by ALK2kinase, which comprises administering to a patient a therapeutically effective amount of a compound of the general formulae (I) - (III) or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the same, wherein the disease having a pathological feature mediated by ALK2kinase is selected from cancers, wherein the cancers are selected from prostate cancer, breast cancer, cervical cancer, endometrial cancer, colon cancer, gastric cancer, lung cancer, liver cancer, bladder cancer, pancreatic cancer, rectal cancer, skin cancer (including melanoma and basal cell carcinoma), oral cancer, bone cancer, ovarian cancer, brain cancer, head and neck cancer, mesothelial intimal cancer, leukemia, lymphoma, esophageal cancer, kidney cancer, thyroid cancer, myeloma, choriocarcinoma, testicular cancer, glioma, maternal glioma, cancer, and the like, Fallopian tube tumors, myelofibrosis, polycythemia vera, or essential thrombocythemia.
Process for producing compound or intermediate
Specific examples are set forth below to illustrate the invention. It is to be understood that the invention is not limited to these examples, which are provided solely to provide methods of practicing the invention and are not intended to limit the scope of the invention in any way.
The compounds provided herein can be prepared by standard synthetic methods well known in the art, and the general methods for preparing the compounds of the invention are provided herein. The starting materials are generally commercially available, for example, via Alfa
Figure PCTCN2019128246-APPB-000009
Sigma-
Figure PCTCN2019128246-APPB-000010
TCI, dynberg reagent, dywagnan chemical limited, dynocolon chemical reagent factory, and the like, or prepared by methods known to those skilled in the art.
The following reaction methods and synthetic steps provide possible routes for the synthesis of the compounds of the invention as well as key intermediates. For a more detailed description of the individual reaction steps, reference is made to the following examples. It will be appreciated by those skilled in the art that the compounds of the invention may also be obtained by other synthetic routes. Although specific starting materials and reagents are used in the reaction schemes below, these starting materials and reagents may be substituted with other similar starting materials or reagents to provide various derivatives. In addition, many of the compounds made by the methods described below may be further modified by conventional chemical methods well known to those skilled in the art, given the benefit of this disclosure.
The compounds of the invention and the corresponding preparation processes are further illustrated and exemplified below by means of examples and preparations. It is to be understood that although typical or preferred reaction conditions (e.g., reaction temperature, time, molar ratios of reactants, reaction solvent, and pressure, etc.) are given in the specific examples, other reaction conditions may be used by one skilled in the art. Optimal reaction conditions may vary with the particular reaction substrate or solvent used, but the conditions may be determined by one of skill in the art through routine optimization.
The starting materials, intermediates and compounds of the examples can be isolated and purified by conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation and chromatography (e.g., column chromatography, TLC separation and purification, etc.).
Commercial solvents and reagents used in the test were used without specific indication, and were used without further purification or treatment after purchase. The reaction conditions (reaction temperature, reaction solvent, molar ratio of reactants, or/and reaction duration) may be different when referring to other examples or synthetic methods. In general, the progress of the reaction can be monitored by TLC, whereby the reaction is terminated and worked up at a suitable time. The purification conditions of the compounds may also vary, generally speaking, according to R of TLCfThe appropriate column chromatography eluent is selected or the corresponding compound is isolated and purified by preparative TLC.
The compounds of formula (I) of the present invention can be prepared according to scheme 1 below. The intermediate A and the intermediate B are respectively carried out in acidic (trifluoroacetic acid, formic acid, acetic acid, oxalic acid, diluted hydrochloric acid and the like) or basic (triethylamine, N-diisopropylethylamine, pyridine, 4-dimethylaminopyridine, N-methylmorpholine and the like)Etc.) in a suitable solvent (n-butanol, methanol, ethanol, dichloromethane, tetrahydrofuran, dioxane, dimethylformamide, 1-methyl-2-pyrrolidone, etc.) at a suitable temperature to produce the compound of formula (I). It will be appreciated that these reaction conditions are not limiting and that the process described can be used to prepare compounds of formula (I) by varying the reaction conditions reasonably. Wherein R is1、R 2、R 3、R 4、R 5、R 6M and X have the definitions as described herein and L is a leaving group.
Scheme 1
Figure PCTCN2019128246-APPB-000011
The following examples are intended to illustrate specific embodiments of the invention and are not intended to limit the scope of the invention described or claimed in any way. One skilled in the art will recognize that the starting materials may be varied and additional steps may be employed to produce compounds encompassed by the present invention, as demonstrated in the examples below. The following examples are for illustrative purposes only and are not intended to, nor should they be construed as, limiting the invention in any way. Those skilled in the art will recognize that variations and modifications can be made without departing from the spirit or scope of the invention.
4 2EXAMPLE 1 preparation of N- (2,2' -bipyridin-3-yl) -N- (7-methoxybenzo [ d ]][1,3]Dioxol-5-yl) pyrimidine-2, 4-diamines Compound 1)
Figure PCTCN2019128246-APPB-000012
Figure PCTCN2019128246-APPB-000013
In a round-bottom flask, N- (2-chloropyrimidin-4-yl) -2,2' -bipyridin-3-amine (100mg, 0.35mmol) (see preparation method WO 2014151871A 2), 7-methoxybenzo [ d ] were added in this order][1,3]Dioxol-5-amine (88.4mg, 0.53mmol) (preparation method J.Chin.chem.Soc.,2001,48,59-63), TFA (157uL, 2.11mmol) and 5mL n-BuOH were reacted at 85 ℃ for 1.5h under argon. After the reaction is finished, cooling to room temperature, adding saturated sodium bicarbonate solution, extracting with DCM (20mL multiplied by 3), drying the organic layer with anhydrous sodium sulfate, and removing the solvent to obtain a crude product; the crude product was purified by slurrying with DCM and EA respectively to give compound 1(122mg, off-white solid, 84.2% yield).1H NMR(DMSO-d 6,400MHz,ppm):δ＝12.86(s,1H),9.22-9.18(m,2H),8.79-8.78(m,1H),8.58-8.56(d,J＝8.2Hz,1H),8.37-8.35(dd,J＝4.4,1.4Hz,1H),8.13-8.12(d,J＝5.7Hz,1H),8.08-8.04(m,1H),7.56-7.52(m,1H),7.43-7.40(m,1H),7.17(s,1H),6.96(s,1H),6.48-6.46(d,J＝5.7Hz,1H),5.95(s,2H),3.79(s,3H).ESI-MS m/z：415.4[M+H] +.
4 2EXAMPLE 2 preparation of N- (2,2' -bipyridin-3-yl) -N- (8-methoxy-2, 3-dihydrobenzo [ b ]][1,4]Dioxin-6-yl) pyrimidine-2, 4- Diamine (Compound 2)
Figure PCTCN2019128246-APPB-000014
4 2Preparation of N- (2,2' -bipyridin-3-yl) -N- (8-methoxy-2, 3-dihydrobenzo [ b ]][1,4]Dioxin-6-yl) pyrimidine-2, 4-diamines Thing 2)
Figure PCTCN2019128246-APPB-000015
In a round-bottomed flask, N- (2-chloropyrimidin-4-yl) -2,2' -bipyridin-3-amine (100mg, 0.35mmol), 8-methoxy-2, 3-dihydrobenzo [ b ] was added in this order][1,4]Dioxin-6-amine (96mg, 0.53mmol) (preparation methods refer to J.Chin.chem.Soc.,2001,48,59-63 and J.Med.chem.2004,47,3823-3842), TFA (157uL, 2.11mmol) and 3mL of n-BuOH, and reacted at 85 ℃ for 1h under argon protection. After the reaction was completed, it was cooled to room temperature, water was added, DCM (20mL × 3) was extracted, the organic layer was dried over anhydrous sodium sulfate, the solvent was removed, and compound 2 was purified by silica gel column (DCM: MeOH ═ 50: 1) to obtain (115mg, white solid, yield 76.7%).1H NMR(CDCl 3,400MHz,ppm):δ＝12.87(s,1H),9.12-9.09(dd,J＝8.5,1.2Hz,1H),8.64-8.61(m,2H),8.32-8.30(dd,J＝4.4,1.3Hz,1H),8.09-8.07(d,J＝5.7Hz,1H),7.91-7.85(m,1H),7.35-7.31(m,1H),7.28-7.25(m,2H),6.84-6.83(d,J＝2.3Hz,1H),6.75-6.74(d,J＝2.3Hz,1H),6.24-6.22(d,J＝5.7Hz,1H),4.34-4.29(m,4H),3.81(s,3H). 13C NMR(CDCl 3,100MHz,ppm):δ＝160.6,160.1,158.4,156.6,148.7,146.3,143.9,141.7,139.6,137.4,137.3,132.7,129.1,128.8,124.1,123.4,122.9,102.8,100.5,98.5,64.5,56.2.ESI MS(M+H) +＝429.4.
2 4Example 3 preparation of N- (7-methoxybenzo [ d ]][1,3]Dioxol-5-yl) -N- (6-methyl-2, 2' -bipyridin-3-yl) pyrimidine-2, 4- Diamine (Compound 3)
Figure PCTCN2019128246-APPB-000016
Referring to the preparation scheme of scheme 1, compound 3, ESI-MS: 429.4[ M + H] +。
4 2Example 4 preparation of N- (2,2' -bipyridin-3-yl) -5-chloro-N- (7-methoxybenzo [ d][1,3]Dioxolen-5-yl) pyrimidine-2, 4-diamines (Compound 4)
Figure PCTCN2019128246-APPB-000017
Referring to the preparation scheme of scheme 1, compound 4, ESI-MS: 449.3[ M + H ]] +。
4 2EXAMPLE 5 preparation of N- (2,2' -bipyridin-3-yl) -5-methoxy-N- (8-methoxy-2, 3-dihydrobenzo [ b ]][1,4]Dioxin-6-yl) Pyrimidine-2, 4-diamine (Compound 5)
Figure PCTCN2019128246-APPB-000018
Referring to the preparation scheme of scheme 1, compound 5, ESI-MS: 459.3[ M + H] +。
4 2Example 6 preparation of N- (2,2' -bipyridin-3-yl) -N- (7-methoxy-2, 2-dimethylbenzo [ d][1,3]Dioxol-5-yl) pyrimidine-2, 4- Diamine (Compound 6)
Figure PCTCN2019128246-APPB-000019
Referring to the preparation scheme of scheme 1, compound 6, ESI-MS: 443.2[ M + H] +。
Biological assay
1. Test for inhibitory Activity of Compound on ALK2
Detection was performed using the ALK2Kinase Enzyme System kit from Promega. First, reagents for kinase detection were formulated, including: 4x Kinase buffer 250. mu.L (containing 200. mu.M DTT); ② 5x Inhibitor mother liquor, namely preparing the tested compound into 10mM mother liquor by DMSO, and then testing the tested compound by DMSOThe compound was diluted to 5mM (20. mu.L of 10mM test compound stock + 20. mu.L DMSO dissolved); ③ 200. mu.L of 1xKinase buffer (containing 1% DMSO); 40 mu L of 1x Kinase buffer; kinase solution 115 uL; sixthly, 120 mu L of Substrate Mix (containing 65 mu M ATP). Then preparing inhibitor working solution, namely preparing a tested compound into 5mM mother solution by DMSO, adding 1 mu L of 5mM mother solution into 99 mu L of 1xKinase buffer, and diluting to 50000nM concentration; subsequently, 20. mu.L of the concentration solution was added to 80. mu.L of 1xKinase buffer (containing 1% DMSO) to obtain a concentration of 10000nM, and 5-fold dilution was performed in this manner to set up 6 concentration gradients. mu.L of each concentration of test compound was added to 384 well plates followed by 2. mu.L of Kinase solution (160mM Tris, 7.5; 80mM MgCl) per well2(ii) a 0.4mg/ml BSA; 200 μ M DTT; ALK2 kinase), centrifugation at 1000rpm for 20s at room temperature, and incubation at 25 ℃ for 30 min; subsequently, 2. mu.L of a mixture containing ATP and kinase substrate was added to each well, centrifuged at 1000rpm for 20s at room temperature, and incubated at 25 ℃ for 120 min. Then 5. mu.L of ADP-Glo per well was addedTMReagents, incubated at 25 ℃ for 40 min; finally, 10 mul of Kinase Detection solution (Kinase Detection Reagent) is added into each hole, and the mixture is incubated at 25 ℃ for 30min and then detected; chemiluminescence values (luminescence) were recorded with a microplate reader, IC of the test substances on ALK2kinase activity was calculated using Origin 7.5 fitting curve50(nM) values.
Table 1 results of the test for inhibitory activity of compounds on ALK 2.
Figure PCTCN2019128246-APPB-000020
Compound I is compound 12 of the patent prepared according to WO2014151871 a 2.
IC A, B, C in Table 150The value ranges are respectively: a is less than or equal to 150nM and 150nM<B<500nM，C≥500nM。
Test results show that the compound of the embodiment of the invention has a remarkable inhibitory effect on ALK2 kinase.
2. Inhibition assay of Compounds on Hepcidin (Hepcidin) expression in HepG2 cells
HepG2 cells (ATCC HB-8065) in the exponential growth phase were digested with pancreatin-EDTA, inoculated at 5000 cells/well into 96-well plates, and after 24 hours of culture in MEM (10% FBS) medium at 37 ℃ under 5% CO2, test compounds were added to each well at a gradient concentration diluted in DMSO medium. The test compound was prepared by first preparing a stock solution of the compound at a concentration of 10mM, and then diluting the compound in a gradient of 8 gradients with a maximum concentration of 10. mu.M for compound detection, 5-fold dilution. The diluted compounds were added to a 96-well plate plated with cells at 50. mu.L per well. Adding the reagent, placing the mixture into an incubator with 37 ℃ and 5% CO2, incubating for 48 hours, centrifuging a 96-well plate at room temperature for 1000rpm multiplied by 5min after the incubation is finished, taking supernatant, and completing the sample adding and detection of an ELISA sample within 30 min. The Hepcidin protein was quantitatively detected with a Hepcidin ELISA Kit (Human Hepcidin Quantikine ELISA Kit, R & D systems, Cat # DHP 250). Preparing a detection reagent comprises the following steps: calibrator dilution RD 5-2680 mL, Wash Buffer 500mL, Substrate Solution 30mL (color development reagent A15 mL and B15 mL are mixed in equal volume and then used in the dark within 15 minutes, the final volume of each hole is 200 μ L), human Hepcidin standard: the final concentration of the recombinant human Hepcidin standard is 1000, 500, 250, 125, 62.5, 31.3, 15.6 and 0 (pg/mL). 50 μ L of Assay dilution RD1-21 was added to each well. Add 50. mu.L of standard, control or sample to each well, seal, and incubate for 2 hours at room temperature. The liquid in the wells was aspirated and 400. mu.L of Wash Buffer was added to Wash the plates 4 times, with the residual liquid being aspirated off each time and the next Wash. mu.L of human Hepcidin binding solution was added to each well, covered with a new seal, and incubated at room temperature for 2 hours. The liquid in the wells was aspirated and 400. mu.L of Wash Buffer was added to Wash the plates 4 times, with the residual liquid being aspirated off each time and the next Wash. Add 200. mu.L of Substrate Solution to each well, protected from light, and incubate for 30min at room temperature. Add 50. mu.L of Stop Solution to each well, and the color should change from blue to yellow in the wells. If the wells are green or the color changes are inconsistent, the reaction plate is tapped gently to mix well. After washing and color development, an enzyme-labeling instrument is used for measuring the absorbance value at 450nM, the concentration of the hepcidin protein in a detection sample is calculated according to a human hepcidin protein determination standard curve, the curve is fitted by Origin 7.5 software, and the IC50 value (nM) of the tested compound for inhibiting HepG2 cells from generating the hepcidin protein is calculated.
TABLE 2 results of compounds tested for inhibitory activity against Hepcidin in HepG2 cells.
Figure PCTCN2019128246-APPB-000021
Compound I is compound 12 of the patent prepared according to WO2014151871 a 2.
IC A, B, C in Table 150The value ranges are respectively: a is less than or equal to 200nM and 200nM<B<500nM，C≥500nM。
Test results show that the compounds of the embodiment of the invention have a remarkable inhibiting effect on the expression of Hepcidin in HepG2 cells.

Claims (16)

  1. A compound of formula (I):
    Figure PCTCN2019128246-APPB-100001
    a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
    x is- (CR)7R 8) p-；
    R 1Selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, 3-to 8-membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl, wherein alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl may be optionally substituted;
    R 2selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9or-NR9COR 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 3、R 4and R5Each independently selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl, wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl, saturated or unsaturated heterocyclyl, oxo or 3-8 membered cycloalkyl; wherein the alkyl, alkenyl, alkynyl, heterocyclic or cycloalkyl group may be optionally substituted;
    R 9、R 10and R11Each independently selected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R12Substituted saturated or unsaturated heterocyclic ring;
    each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
    m is 0, 1,2 or 3;
    p is 1,2 or 3;
    q is 0, 1,2 or 3.
  2. The compound of claim 1, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein the compound is according to formula (II):
    Figure PCTCN2019128246-APPB-100002
    x is- (CR)7R 8) p-；
    R 1Selected from aryl or heteroaryl groups which may be optionally substituted;
    R 2selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9or-NR9COR 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 3、R 4and R5Each independently selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl, wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 7and R8Are each independently selected from-HHalogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl, saturated or unsaturated heterocyclyl, oxo or 3-8 membered cycloalkyl; wherein the alkyl, alkenyl, alkynyl, heterocyclic or cycloalkyl group may be optionally substituted;
    R 9、R 10and R11Each independently selected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R12Substituted saturated or unsaturated heterocyclic ring;
    each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
    p is 1,2 or 3;
    q is 0, 1,2 or 3.
  3. The compound of claim 2, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein the compound is according to formula (III):
    Figure PCTCN2019128246-APPB-100003
    x is- (CR)7R 8) p-；
    R 1Is selected from heteroaryl which may be optionally substituted;
    R 2selected from-H, halogen or-C1-6An alkyl group; wherein alkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
    R 3and R4Are respectively independentIs selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-(CH 2) qNR 9R 10-、-CONR 9R 10、-NO 2、C 1-6Alkyl radical, C2-6Alkenyl radical, C2-6Alkynyl, heteroalkyl, -OR9、-COR 9、-COOR 9、-SO 2R 9、-NR 9COR 10、-NR 9CONR 10R 11、-NR 9CO 2R 10、-NR 9SO 2NR 10R 11or-NR9SO 2R 10Wherein alkyl, alkenyl, alkynyl or heteroalkyl may be optionally substituted;
    R 6selected from-H, halogen, -OH, -CN, -CF3、-NO 2、-C 1-6An alkyl or heteroalkyl group, wherein the alkyl or heteroalkyl group may be optionally substituted;
    R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl, heteroalkyl, -C2-6Alkenyl, -C2-6Alkynyl or oxo; wherein alkyl, alkenyl or alkynyl may be selected from-H, halogen, -C1-4Alkyl substituent substitution;
    R 9、R 10and R11Each independently selected from-H, heteroalkyl, -C1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl, 3-8 membered cycloalkyl, saturated or unsaturated heterocyclyl, aryl or heteroaryl; wherein (R)9And R10) And/or (R)10And R11) Together with the nitrogen atom to which they are attached form a group which may be substituted by at least one R 12Substituted saturated or unsaturated heterocyclic ring;
    each R12Each independently selected from-H, halogen, -C1-6Alkyl or oxo;
    p is 1,2 or 3;
    q is 0, 1,2 or 3.
  4. The compound of claim 3, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
    x is- (CR)7R 8) p-；
    R 1Selected from pyridyl optionally substituted;
    R 2selected from-H, halogen or-C1-6An alkyl group; wherein alkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
    R 3and R4Each independently selected from-H, halogen, -C1-6Alkyl or heteroalkyl; wherein alkyl or heteroalkyl may be selected from-H, halogen, -C1-4Alkyl or oxo;
    R 6selected from-H, halogen, -OH, -CN, -C1-6Alkyl or-C1-6An alkoxy group; wherein alkyl or alkoxy may be selected from-H, halogen, -C1-4Alkyl or oxo;
    R 7and R8Each independently selected from-H, halogen, -C1-6Alkyl or-C1-6Alkoxy, wherein alkyl or alkoxy may be selected from-H, halogen or-C1-4Alkyl substituent substitution;
    p is 1 or 2.
  5. The compound of claim 4, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
    x is- (CR)7R 8) p-；
    R 1Is composed of
    Figure PCTCN2019128246-APPB-100004
    Wherein R is13Selected from-H, halogen, -OH, -CN, -CF3、-CHF 2、-CH 2F、-OCF 3、-NO 2、-NH 2、-C 1-6Alkyl, -C2-6Alkenyl, -C2-6Alkynyl or heteroalkyl;
    R 2selected from-H, halogen or C1-6An alkyl group;
    R 3and R4Each independently selected from-H, halogen, C1-6Alkyl or-C1-6Alkoxy, wherein alkyl or alkoxy may be selected from-H, halogen or-C1-4Alkyl or oxo;
    R 6selected from-H, halogen, -OH, -CN, -C1-6Alkyl or-C1-6An alkoxy group;
    R 7and R8Each independently selected from-H, halogen or-C1-6Alkyl, wherein alkyl may be selected from-H, halogen or-C1-4Alkyl substituent substitution;
    p is 1 or 2.
  6. The compound of claim 5, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, wherein:
    x is- (CR)7R 8) p-；
    R 1Is composed of
    Figure PCTCN2019128246-APPB-100005
    Wherein R is13Selected from-H, halogen or-C1-4An alkyl group;
    R 2is selected from-H or-C1-4An alkyl group;
    R 3is selected from-H, -C1-4Alkyl or-C1-4An alkoxy group;
    R 4is selected from-H or-C1-4An alkyl group;
    R 6selected from-H, halogen, -CN, -C1-4Alkyl or-C1-4An alkoxy group;
    R 7and R8Each independently selected from-H or-C1-4An alkyl group;
    p is 1 or 2.
  7. The compound of claims 1 to 6, a pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, selected from:
    Figure PCTCN2019128246-APPB-100006
    Figure PCTCN2019128246-APPB-100007
  8. the compound of claims 1 to 7, pharmaceutically acceptable salt, hydrate, solvate, or stereoisomer thereof, selected from:
    Figure PCTCN2019128246-APPB-100008
  9. a process for the preparation of a compound of formula (I), a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 8, comprising the steps of:
    Figure PCTCN2019128246-APPB-100009
    wherein R is1、R 2、R 3、R 4、R 5And R6As defined in claim 1;
    the intermediate A and the intermediate B react under acidic or basic conditions in a suitable solvent at a suitable temperature to generate the compound of the formula (I).
  10. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable carrier, diluent or excipient thereof.
  11. Use of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 10, for the manufacture of a medicament for the prevention and/or treatment of a disease having a pathological feature mediated by ALK2 kinase.
  12. The use according to claim 11, wherein the disease having pathological features mediated by ALK2kinase is anemia.
  13. The use according to claim 11, wherein the disease having pathological features mediated by ALK2kinase is cancer.
  14. A method for the therapeutic prevention and/or therapeutic prevention of a disease having a pathological feature mediated by ALK2kinase, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1-8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 10, wherein the disease having a pathological feature mediated by ALK2kinase is selected from anemia or cancer.
  15. A method for the therapeutic prevention and/or therapeutic prevention of a disease having a pathological feature mediated by ALK2kinase, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 10, wherein the disease having a pathological feature mediated by ALK2kinase is anemia, wherein the anemia is selected from anemia of chronic disease, anemia of chronic inflammation, cancer, or anemia of progressive fibrodysplasia.
  16. A method for the treatment and/or prophylaxis of a disease having a pathological feature mediated by ALK2kinase, comprising administering to a patient a therapeutically effective amount of a compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 10, wherein the disease having a pathological feature mediated by ALK2kinase is a cancer, wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, cervical cancer, endometrial cancer, colon cancer, gastric cancer, lung cancer, liver cancer, bladder cancer, pancreatic cancer, rectal cancer, skin cancer (including melanoma and basal cell carcinoma), oral cancer, bone cancer, ovarian cancer, brain cancer, head and neck cancer, mesothelial intimal cancer, leukemia, lymphoma, esophageal cancer, renal cancer, thyroid cancer, myeloma, choriocarcinoma, testicular cancer, glioma, maternal glioma, or prostate cancer, Fallopian tube tumors, myelofibrosis, polycythemia vera, or essential thrombocythemia.
CN201980086260.6A 2018-12-26 2019-12-25 2, 4-diaminopyrimidine derivatives Active CN113227080B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2018115946616 2018-12-26
CN201811594661.6A CN111362928A (en) 2018-12-26 2018-12-26 2, 4-diaminopyrimidine derivatives
PCT/CN2019/128246 WO2020135489A1 (en) 2018-12-26 2019-12-25 2,4-diaminopyrimidine derivatives

Publications (2)

Publication Number Publication Date
CN113227080A true CN113227080A (en) 2021-08-06
CN113227080B CN113227080B (en) 2023-08-15

Family

ID=71126370

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811594661.6A Withdrawn CN111362928A (en) 2018-12-26 2018-12-26 2, 4-diaminopyrimidine derivatives
CN201980086260.6A Active CN113227080B (en) 2018-12-26 2019-12-25 2, 4-diaminopyrimidine derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201811594661.6A Withdrawn CN111362928A (en) 2018-12-26 2018-12-26 2, 4-diaminopyrimidine derivatives

Country Status (2)

Country Link
CN (2) CN111362928A (en)
WO (1) WO2020135489A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
CN1678321A (en) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN105308033A (en) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 JAK2 and ALK2 inhibitors and methods for their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014183300A1 (en) * 2013-05-17 2014-11-20 Suzhou Vivotide Biotechnologies Co., Ltd. Vegfr tyrosine kinase inhibitors
CA2959347C (en) * 2014-08-25 2023-03-07 Salk Institute For Biological Studies Ulk1 inhibitors and methods using same
WO2017066428A1 (en) * 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018021A1 (en) * 2001-08-22 2003-03-06 Amgen Inc. 2,4-disubstituted pyrimidinyl derivatives for use as anticancer agents
US20040063705A1 (en) * 2001-08-22 2004-04-01 Jean-Christophe Harmange Substituted pyrimidinyl derivatives and methods of use
CN1678321A (en) * 2002-07-29 2005-10-05 里格尔药品股份有限公司 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
CN105308033A (en) * 2013-03-14 2016-02-03 特雷罗药物股份有限公司 JAK2 and ALK2 inhibitors and methods for their use

Also Published As

Publication number Publication date
CN113227080B (en) 2023-08-15
WO2020135489A1 (en) 2020-07-02
CN111362928A (en) 2020-07-03

Similar Documents

Publication Publication Date Title
EP2365970B1 (en) Pyridazinones and their use as btk inhibitors
CN112955459A (en) Bicyclic peptide ligands and uses thereof
ES2477878T3 (en) Compounds and compositions of 5- (4- (aloalkoxy) phenyl) pyrimidin-2-amine as kinase inhibitors
SG183302A1 (en) Androgen receptor modulators and uses thereof
CA2908098A1 (en) Mk2 inhibitors and uses thereof
WO2020035020A1 (en) Imidazopyridine derivative, preparation method therefor, and application thereof in medicine
JP2023513854A (en) Macrocycles and uses thereof
BR112019015256A2 (en) selected compound of a substance of formula 1 and a pharmaceutically acceptable salt thereof, and pharmaceutical composition
EP3596084A1 (en) 9,10,11,12-tetrahydro-8h-[1,4]diazepino[5&#39;,6&#39;:4,5]thieno[3,2-f]quinolin-8-one compounds and uses thereof
CN103382206A (en) Quinoline or quinazoline derivative, its preparation method and application in medicines
TWI580679B (en) Heteroaryl-pyrimidine derivatives, preparation process and pharmaceutical use thereof
TW201821427A (en) Bicyclic heteroaryl derivatives
JP2020511468A (en) Deuterated analogs of MK2 inhibitors and uses thereof
EP3936509A1 (en) Fgfr4 kinase inhibitor, preparation method therefor and use thereof
JP2020525469A (en) New quinolinone compound
JP2019534266A (en) Bridged ring derivative of 5-membered heteroaryl ring, process for its preparation and medical use thereof
BR112020010004A2 (en) pyrazolopyridinone compounds
CN112094269B (en) Saturated six-membered ring heterocyclic compound, preparation method and application
BR112020010012A2 (en) pyrazolopyridinone compounds
KR20170113627A (en) S100-imidazo [2,1-b] thiazole and 5,6-dihydroimidazo [2,1-b] thiazole derivatives
WO2021099838A1 (en) Adenosine receptor antagonist compounds
CA2934257C (en) Imidazolin-5-one derivative useful as fasn inhibitors for the treatment of cancer
JP2006510727A (en) Kinase modulator
CN113227080B (en) 2, 4-diaminopyrimidine derivatives
TW202334167A (en) Fused tetracyclic quinazoline derivatives as inhibitors of erbb2

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant